PD-L1 in Patients with Resected Non-small Cell Lung Cancer
暂无分享,去创建一个
[1] H. Kenmotsu,et al. PD-L1 expression and response to pembrolizumab in patients with EGFR-mutant non-small cell lung cancer. , 2020, Japanese journal of clinical oncology.
[2] F. Tanaka,et al. Prognostic impact of PD-L1 expression in correlation with neutrophil-to-lymphocyte ratio in squamous cell carcinoma of the lung , 2020, Scientific Reports.
[3] G. Freeman,et al. The importance of exosomal PDL1 in tumour immune evasion , 2020, Nature Reviews Immunology.
[4] Yan-Ze Jin,et al. Correlation between PD-L1 expression and clinicopathological characteristics of non-small cell lung cancer: A real-world study of a large Chinese cohort. , 2019, Journal of thoracic disease.
[5] T. Lv,et al. Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients , 2019, Journal of Translational Medicine.
[6] Ce Li,et al. Exosomal PD-L1 Retains Immunosuppressive Activity and is Associated with Gastric Cancer Prognosis , 2019, Annals of Surgical Oncology.
[7] Jianying Zhou,et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial , 2019, The Lancet.
[8] K. Shimizu,et al. Comparative study of the PD-L1 expression and CD8+ tumor-infiltrating lymphocyte between surgically resected and matched re-biopsy specimens in recurrent non-small cell lung cancer , 2019, Therapeutics and clinical risk management.
[9] R. Blelloch,et al. Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory , 2019, Cell.
[10] E. Jaffee,et al. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. , 2019, JCI insight.
[11] L. Landi,et al. Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer , 2019, Oncotarget.
[12] A. Tafreshi,et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] F. Barlesi,et al. The clinical utility of tumor mutational burden in non-small cell lung cancer. , 2018, Translational lung cancer research.
[14] R. Boidot,et al. Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy , 2018, British Journal of Cancer.
[15] Kongming Wu,et al. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors , 2018, Molecular Cancer.
[16] A. Ceribelli,et al. Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC , 2018, AntiCancer Research.
[17] Wei Zhang,et al. Exosomal PD-L1 Contributes to Immunosuppression and is Associated with anti-PD-1 Response , 2018, Nature.
[18] Ahmet Zehir,et al. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Ji-Young Hong,et al. The role of exosomes and miRNAs in drug‐resistance of cancer cells , 2017, International journal of cancer.
[20] F. Grossi,et al. Exosomes: a new horizon in lung cancer. , 2017, Drug discovery today.
[21] J. Pignon,et al. PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] Y. Murakumo,et al. Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung Cancer , 2017, Oncology.
[23] Y. Maehara,et al. The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma. , 2017, Lung cancer.
[24] Masato Takahashi,et al. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC) , 2017, Breast Cancer.
[25] Andreas Möller,et al. The Biodistribution and Immune Suppressive Effects of Breast Cancer-Derived Exosomes. , 2016, Cancer research.
[26] Y. Shentu,et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.
[27] Jinming Yu,et al. Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions , 2016, Oncotarget.
[28] S. Digumarthy,et al. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis , 2016, Clinical Cancer Research.
[29] Y. Shentu,et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.
[30] R. Herbst,et al. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. , 2016, JAMA oncology.
[31] J. Madore,et al. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. , 2015, Lung cancer.
[32] Michael A. Hollingsworth,et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver , 2015, Nature Cell Biology.
[33] Antoni Ribas,et al. Classifying Cancers Based on T-cell Infiltration and PD-L1. , 2015, Cancer research.
[34] J. Lunceford,et al. Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.
[35] H. Ditzel,et al. Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non–Small Cell Lung Cancer , 2015, Clinical Cancer Research.
[36] S. Thongprasert,et al. A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER) , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[37] A. Dutt,et al. Frequency of EGFR Mutations in 907 Lung Adenocarcioma Patients of Indian Ethnicity , 2013, PloS one.
[38] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[39] Raghu Kalluri,et al. Exosomes in tumor microenvironment influence cancer progression and metastasis , 2013, Journal of Molecular Medicine.
[40] Gema Moreno-Bueno,et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET , 2012, Nature Medicine.
[41] E. Ruffini,et al. Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. , 2009, The Annals of thoracic surgery.
[42] Laurence Zitvogel,et al. Exosomes: composition, biogenesis and function , 2002, Nature Reviews Immunology.